GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice

Annals of the Rheumatic Diseases

Volumn 66, Issue 4, 2007, Pages 452-457

  Plater Zyberk, C ^a   Joosten, L A B ^b   Helsen, M M A ^b   Hepp, J ^a   Baeuerle, P A ^a   Van Den Berg, W B ^b  

^a MICROMET AG   (Germany)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DEXAMETHASONE; ETANERCEPT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 22E9; PROTEOGLYCAN; TECHNETIUM 99M; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL ARTHRITIS; BACTERIAL CELL WALL; CARTILAGE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; HISTOLOGY; INFLAMMATION; JOINT SWELLING; MALE; MONARTHRITIS; MOUSE; NONHUMAN; PATELLA; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; STREPTOCOCCUS;

ACUTE DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, EXPERIMENTAL; CARTILAGE, ARTICULAR; CELL WALL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INTERLEUKIN-1BETA; MALE; MICE; MICE, INBRED C57BL; PROTEOGLYCANS; STREPTOCOCCUS PYOGENES; SYNOVIAL MEMBRANE;

EID: 34147198271     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.057182     Document Type: Article

References (44)

1. Diederichs K, Boone T, Karplus PA. Novel fold and putative receptor binding site of granulocyte-macrophage colony-stimulating factor. Science 1991;254:1779-82.
2. Barreda DR, Hanington PC, Belosevic M. Regulation of myeloid development and function by colony stimulating factors. Dev Comp Immunol 2004;28:509-54.
3. Sheridan JW, Metcalf D. A low molecular weight factor in lung-conditioned medium stimulating granulocyte and monocyte colony formation in vitro. J Cell Physiol 1973;81:11-23.
4. Baldwin GC. The biology of granulocyte-macrophage colony-stimulating factor: effects on hematopoietic and nonhematopoietic cells. Dev Biol 1992;151:352-67.
5. Fleetwood AJ, Cook AD, Hamilton JA. Functions of granulocyte-macrophage colony-stimulating factor. Crit Rev Immunol 2005;25:405-28.
6. Hamilton JA, Anderson GP. GM-CSF Biology. Growth Factors 2004;22:225-31.
7. Wang J, Snider DP, Hewlett BR, Lukacs NW, Gauldie J, Liang H, et al. Transgenic expression of granulocyte-macrophage colony-stimulating factor induces the differentiation and activation of a novel dendritic cell population in the lung. Blood 2000;95:2337-45.
8. Stanley E, Lieschke GJ, Grail D, Metcalf D, Hodgson G, Gall JA, et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci USA 1994;91:5592-6.
9. Hamilton JA. GM-CSF in inflammation and autoimmunity. Trends Immunol 2002;23:403-8.
10. Feldmann M, Maini RN. Rheumatoid arthritis: introduction. Springer Semin Immunopathol 1998;20:3-4.
11. Feldmann M, Londei M, Grubeck-Loebenstein B, De Berardinis P, Leech Z, Turner M, et al. Understanding what infiltrating cells do in autoimmunity: combination of cellular and molecular approaches. Transplant Proc 1988;20:311-14.
12. Alvaro-Gracia JM, Zvaifler NJ, Brown CB, Kaushansky K, Firestein GS. Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-alpha. J Immunol 1991;146:3365-71.
13. Ulfgren AK, Lindblad S, Klareskog L, Andersson J, Andersson U. Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis 1995;54:654-61.
14. Fiehn C, Wermann M, Pezzutto A, Hufner M, Heilig B. Plasma GM-CSF concentrations in rheumatoid arthritis, systemic lupus erythematosus and spondyloarthropathy. Z Rheumatol 1992;51:121-6.
15. Cook AD, Braine EL, Campbell IK, Rich MJ, Hamilton JA. Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. Arthritis Res 2001;3:293-8.
16. Campbell IK, Rich MJ, Bischof RJ, Dunn AR, Grail D, Hamilton JA. Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice. J Immunol 1998;161:3639- 44.
17. Campbell IK, Bendele A, Smith DA, Hamilton JA. Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice. Ann Rheum Dis 1997;56:364-8.
18. Hazenberg BP, Van Leeuwen MA, Van Rijswijk MH, Stern AC, Vellenga E. Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colony-stimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis. Blood 1989;74:2769-70.
19. de Vries EG, Willemse PH, Biesma B, Stern AC, Limburg PC, Vellenga E. Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy. Lancet 1991;24:517-8.
20. van den Broek MF, van den Berg WB, van de Putte LB, Severijnen AJ. Streptococcal cell wall-induced arthritis and flare-up reaction in mice induced by homologous or heterologous cell walls. Am J Pathol 1988;133:139-49.
21. Kuiper S, Joosten LA, Bendele AM, Edwards CK 3rd, Arntz OJ, Helsen MM, et al. Different roles of tumour necrosis factor alpha and interleukin 1 in murine streptococcal cell wall arthritis. Cytokine 1998;10:690-702.
22. Joosten LA, Helsen MM, van Den Berg WB. Blockade of endogenous interleukin 12 results in suppression of murine streptococcal cell wall arthritis by enhancement of interleukin 10 and intedeukin 1Ra. Ann Rheum Dis 2000;59:196-205.
23. Wooley PH, Dutcher J, Widmer MB, Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993;151:6602-7.
24. Murray KM, Dahl SL. Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis. Ann Pharmacother 1997;31:1335-8.
25. Sommer C, Schafers M, Marziniak M, Toyka KV. Etanercept reduces hyperalgesia in experimental painful neuropathy. J Peripher Nerv Syst 2001;6:67-72.
26. Hui-Yuen JS, Duong TT, Yeung RS. TNF-alpha is necessary for induction of coronary artery inflammation and aneurysm formation in an animal model of Kawasaki disease. J Immunol 2006;176:6294-301.
27. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151:1548-61.
28. Vallejo JG, Nemoto S, Ishiyama M, Yu B, Knuefermann P, Diwan A, et al. Functional significance of inflammatory mediators in a murine model of resuscitated hemorrhagic shock. Am J Physiol Heart Circ Physiol 2005;288:H1272-7.
29. Kruijsen MW, van den Berg WB, van de Putte LB, van den Broek WJ. Detection and quantification of experimental joint inflammation in mice by measurement or 99mTc-pertechnetate uptake. Agents Actions 1981;11(6-7):640-2.
30. Joosten LA, van De Loo FA, Lubberts E, Helsen MM, Netea MG, van Der Meer JW, et al. An IFN-gamma-independent proinflammatory role of IL-18 in murine streptococcal cell wall arthritis. J Immunol 2000;165:6553-8.
31. Joosten LA, Koenders MI, Smeets RL, Heuvelmans-Jacobs M, Helsen MM, Takeda K, et al. Toll-like receptor 2 pathway drives streptococcal cell wall-induced joint inflammation: critical role of myeloid differentiation factor 88. J Immunol 2003;171:6145-53.
32. Hamilton K, Clair EW. Tumour necrosis factor-alpha blockade: a new era for effective management of rheumatoid arthritis. Expert Opin Pharmacother 2000;1:1041-52.
33. Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 2000;51:207-29.
34. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594- 602.
35. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
36. Puppo F, Murdoca G, Ghio M, Indiveri F. Emerging biologic drugs for the treatment of rheumatoid arthritis. Autoimmun Rev 2005;4:537-41.
37. Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. Cochrane Database Syst Rev 2005:CD005113.
38. Emery P. Adalimumab therapy: clinical findings and implications for integration into clinical guidelines for rheumatoid arthritis. Drugs Today (Barc) 2005;41:155-63.
39. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85:307-10.
40. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproreinases: role in arthritis. Front Biosci 2006;11:529-43.
41. Mitrovic DR, Darmon N. Structural and biochemical abnormalities of articular cartilage in rheumatoid arthritis. Rheumatol Int 1990;10:31-7.
42. van den Berg WB, Joosten LA, Kollias G, van De Loo FA. Role of tumour necrosis factor alpha in experimental arthritis: separate activity of interleukin 1beta in chronicity and cartilage destruction. Ann Rheum Dis 1999;58(Suppl 1):140-8.
43. Joosten LA, Helsen MM, Saxne T, van De Loo FA, Heinegard D, van Den Berg WB. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol 1999;163:5049-55.
44. van den Berg WB. Uncoupling of inflammatory and destructive mechanisms in arthritis. Semin Arthritis Rheum 2001;30(5 Suppl 2):7-16.